-
Clinical Drug Investigation Feb 2017Cixutumumab is a monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF1R). We sought to evaluate the efficacy of cixutumumab in the treatment of... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND AND OBJECTIVES
Cixutumumab is a monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF1R). We sought to evaluate the efficacy of cixutumumab in the treatment of cancer, and to comprehensively assess the associated adverse events in phase II clinical trials.
METHODS
Data were collected from PubMed, Embase, and Clinicaltrials.gov. The improvement on progression-free survival (PFS) was evaluated by hazard ratio (HR) and 95% confidence intervals (95% CIs). We also carried a meta-analysis to comprehensively evaluate the incidence of adverse events.
RESULTS
The adverse events that were mentioned most frequently were hyperglycemia, anemia, nausea, fatigue, and thrombocytopenia. The most frequent adverse events were hyponatremia (40.28%), fatigue (35.18%), and skin rash (35.11%). Results showed that cixutumumab treatments did not benefit PFS (HR 1.03, 95% CI 0.83-1.26, p = 0.979). The complete response (CR) was rarely seen in phase II trials.
CONCLUSIONS
Cixutumumab was well tolerated when used alone and in combination therapies, but its antitumor activity was low in the existing phase II clinical trials. An acceptable incidence of adverse effects supports further investigation of this drug, provided that it shows antitumor activity in combination with other drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Disease-Free Survival; Humans; Receptor, IGF Type 1; Receptors, Somatomedin
PubMed: 27858328
DOI: 10.1007/s40261-016-0475-y -
Climacteric : the Journal of the... Jun 2016Despite valuable evidence documented on immunological changes in postmenopausal women, particularly following hormone replacement therapy (HRT), it is difficult to... (Review)
Review
BACKGROUND
Despite valuable evidence documented on immunological changes in postmenopausal women, particularly following hormone replacement therapy (HRT), it is difficult to explain whether immunological changes during menopause are caused by HRT. This systematic review aimed to summarize the results of studies available on postmenopausal immunological changes and to determine any potential effects of HRT on the immunological profile of postmenopausal women.
METHODS
For this systematic review, we primarily explored 751 papers about the immune system status of postmenopausal women published during 1955-2015. Scientific databases including Web of Science, MEDLINE, Scopus, Embase, Google Scholar, and the Cochrane database were searched for a number of relevant key terms. Of 209 papers that met the initial search criteria, 13 papers were potentially retrievable and included descriptions of changes in immunological factors during the postmenopausal period and the effects of HRT on such changes.
RESULTS
HRT resulted in a range of immunological changes in postmenopausal women. These changes included reductions in interleukin-2 (IL-2), IL-6, and insulin-like growth factor-1 levels and increments in IL-1 and IL-4 levels. Elevations in B-cell production and estrogen receptor alpha, CD19+ cells, and C3 and C4 complement levels were also documented. Decreased CD8+ counts were also a constant finding in most reviewed papers. However, data on the changes in other factors such as tumor necrosis factor-alpha, interferon-gamma, CD4+, and CD25+ were contradictory. Levels of some immunological factors, e.g. immunoglobulin G (IgG), IgM, and IL-10, remained unchanged following HRT.
CONCLUSION
Postmenopausal women are prone to impaired immune responses. HRT during the menopausal period can mediate immunological responses by inducing significant changes in immunological mediators.
Topics: Estrogen Receptor alpha; Estrogen Replacement Therapy; Female; Humans; Immunity; Immunoglobulins; Insulin-Like Growth Factor I; Interleukin-2; Interleukin-4; Interleukin-6; Interleukins; Lymphocyte Count; MEDLINE; Postmenopause
PubMed: 27086591
DOI: 10.3109/13697137.2016.1164136 -
Menopause (New York, N.Y.) Dec 2017We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the effect of programmed exercise for at least 12 weeks, in... (Meta-Analysis)
Meta-Analysis Review
OBJECTIVE
We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the effect of programmed exercise for at least 12 weeks, in postmenopausal women on insulin sensitivity-related outcomes (ISROs), including fasting insulin, C-peptide, insulin growth factor (IGF-1) and IGF-binding protein (IGFBP-3), Homeostatic Model Assessment-Insulin Resistance (HOMA-IR), and anthropometric variables.
METHODS
Searches were conducted in PubMed-Medline, Embase, Scopus, Web of Science, and Cochrane Library from inception through May 3, 2016, for studies published in all languages. Extracted data included characteristics of the study design, study participants, intervention, and outcome measures. Types of exercise were classified into "mid-term exercise intervention" (MTEI, 3-4 months exercise duration) and a "long-term exercise intervention" (LTEI, 6-12 months exercise duration). Risk of bias in RCTs was evaluated with the Cochrane tool. We used random-effects models for meta-analyses. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
RESULTS
Seven RCTS (n = 580) evaluating the effects of programmed exercise on ISROs were included. In three RCTs, MTEI significantly lowered insulin levels (mean difference [MD] -6.50 pmol/L, 95% confidence interval [CI] -11.19, -1.82, P = 0.006) and HOMA-IR values (MD -0.18, 95% CI -0.34, -0.03, P = 0.02) when compared with controls. LTEI had no significant effect on insulin levels (P = 0.19) or HOMA-IR values (P = 0.68) in four and three RCTs, respectively. There were no significant differences between exercise intervention versus controls in circulating IGF-1, glucose, triglycerides with both MTEI and LTEI, and in IGFBP-3 with LTEI. There were significant reductions in body mass index (BMI, kg/m) (MD -1.48, 95% CI -2.48, -0.48, P = 0.004) and in body fat percentage (MD -2.99, 95% CI -4.85, -1.14, P = 0.01) after MTEI; and in waist circumference after both MTEI (MD -1.87, 95% CI -3.02, -0.72, P = 0.001) and LTEI (MD -3.74, 95% CI -6.68, -0.79). Heterogeneity of effects among studies was moderate to low.
CONCLUSION
Exercising for 3 to 4 months significantly lowered insulin levels and HOMA-IR values, BMI waist circumference, and percentage body fat mass; exercising for 6 to 12 months lowered waist circumference in postmenopausal women.
Topics: Body Composition; Body Mass Index; C-Peptide; Exercise; Fasting; Female; Humans; Insulin; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Life Style; MEDLINE; Postmenopause; Randomized Controlled Trials as Topic; Waist Circumference
PubMed: 28654627
DOI: 10.1097/GME.0000000000000936 -
International Journal of Obesity (2005) May 2022According to studies, there are many inconsistencies in how IGF-1 levels change after bariatric surgery compared to before surgery, as well as its effects. These... (Meta-Analysis)
Meta-Analysis Review
According to studies, there are many inconsistencies in how IGF-1 levels change after bariatric surgery compared to before surgery, as well as its effects. These discrepancies can be attributed to various factors such as age, body mass index (BMI), and duration of intervention. Therefore, the aim of this study was to evaluate the level of insulin-like growth factor-1 (IGF-1) after bariatric surgery. A systematic review and meta-analysis based on the PRISMA guidelines was conducted from inception until 2021. From 1871 articles initially selected, 24 studies with 28 treatment arms met the eligible criteria and were included. Pooled findings from the random-effects model indicated that IGF-1 levels increased significantly [weighted mean difference (WMD) = 8.84 ng/ml; 95% confidence interval (CI) 0.30-17.39; p = 0.043] after bariatric surgery compared to before surgery. No significant heterogeneity was noted among the studies (Cochran Q test, p = 0.90, I = 0.0%). In subgroup analysis, bariatric surgery significantly increased IGF-1 levels at age <40 years but not at age ≤40 years. Bariatric surgery is capable of increasing the IGF-1 levels compared to the period prior to surgery but with a modest clinical magnitude.
Topics: Bariatric Surgery; Body Mass Index; Insulin-Like Growth Factor I
PubMed: 35034953
DOI: 10.1038/s41366-021-01051-6 -
Hormones (Athens, Greece) Jun 2021Findings regarding the effects of resistance training (RT) on muscle strength, serum level of IGF-1, and its binding proteins are contradictory. To resolve this... (Meta-Analysis)
Meta-Analysis
Effects of resistance training on muscle strength, insulin-like growth factor-1, and insulin-like growth factor-binding protein-3 in healthy elderly subjects: a systematic review and meta-analysis of randomized controlled trials.
BACKGROUND
Findings regarding the effects of resistance training (RT) on muscle strength, serum level of IGF-1, and its binding proteins are contradictory. To resolve this contradiction, we performed a systematic review and meta-analysis to investigate the effects of RT on muscle strength, the levels of serum IGF-1, and IGF-binding protein-3 in the elderly and aged.
MATERIALS AND METHODS
The PubMed, CINAHL, Medline, Google Scholar, and Scopus databases and reference lists of included studies were systematically searched to identify randomized controlled trials (RCTs) comparing subjects who underwent RT and control individuals up to May 15, 2020. This study was performed following the Preferred Items for Reporting of Systematic Reviews and Meta-Analyses guidelines. We identified and analyzed 11 eligible trials in this meta-analysis.
RESULTS
Pooled data displayed an overall significant elevation in IGF-1 (mean difference (MD): 17.34 ng/ml; 95% confidence interval (CI): 7.23, 27.46) and in muscle strength in leg press (SMD: 0.82; 95% CI: 0.30, 1.34) and bench press (SMD: 0.82; 95% CI: 0.42, 1.23) following RT. By contrast, the pooled estimate showed a non-significant elevation in IGFBP-3 (MD: 0.13 ng/ml; 95% CI: - 39.39, 39.65). Subgroup analysis revealed that the elevation in serum IGF-1 levels after RT was significant only in women (MD: 19.30 ng/ml); moreover, it increased after intervention durations of both > 12 weeks (MD: 21.98 ng/ml) and of ≤ 12 weeks (MD: 15.31 ng/ml).
CONCLUSION
RT was associated with elevated muscle strength. Moreover, RT was correlated with increased serum levels of IGF-1 among women and among those who received the training for ≤ 12 weeks or > 12 weeks. Further studies are required to elucidate the mechanisms underlying the impact of RT on IGF-1, IGFBP-3, and muscle strength.
Topics: Aged; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Muscle Strength; Randomized Controlled Trials as Topic; Resistance Training
PubMed: 33442864
DOI: 10.1007/s42000-020-00250-6 -
Ophthalmic Genetics 2017To conduct a comprehensive evaluation of the association of Insulin-like growth factor 1 (IGF1) polymorphism rs6214 with high myopia through a systematic review and... (Meta-Analysis)
Meta-Analysis Review
PURPOSE
To conduct a comprehensive evaluation of the association of Insulin-like growth factor 1 (IGF1) polymorphism rs6214 with high myopia through a systematic review and meta-analysis of candidate genetic association study.
METHODS
All case-control association studies on IGF1 and high myopia reported up to 15 June 2016 in PubMed, Embase, Web of Science, and the Chinese Biomedical Database were retrieved. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for single-nucleotide polymorphism (SNP) using fixed and random effects models according to between study heterogeneity. Publication bias analyses were conducted using Begg's test.
RESULTS
A total of eight studies from published articles were included in our analysis. The meta-analyses for IGF1 rs6214, composed of 4242 high myopia patients and 4430 controls, showed low heterogeneity for the included populations in all the genetic models, except that of the allelic genetic model in the pooled populations. The analyses of all the genetic models in Chinese, Japanese, and overall pooled populations did not identify any significant association between high myopia and IGF1 rs6214.
CONCLUSIONS
This meta-analysis showed there was no association detected between IGF1 rs6214 and high myopia. Given the limited sample size, further investigations including more ethnic groups are required to validate the association.
Topics: Alleles; Asian People; Case-Control Studies; China; Genetic Association Studies; Humans; Insulin-Like Growth Factor I; Myopia, Degenerative; Polymorphism, Single Nucleotide
PubMed: 28135889
DOI: 10.1080/13816810.2016.1253105 -
Annals of Palliative Medicine Nov 2020In recent years, a number of studies have shown abnormal levels of peripheral insulin growth factor-1 (IGF-1) in patients with mood disorder, but the results are not... (Meta-Analysis)
Meta-Analysis
BACKGROUND
In recent years, a number of studies have shown abnormal levels of peripheral insulin growth factor-1 (IGF-1) in patients with mood disorder, but the results are not uniform. Therefore, this paper focuses on such studies, conducts a systematic review and meta-analysis, and discusses the factors affecting peripheral IGF-1 in patients with mood disorder.
METHODS
Cochrane database, PubMed database, Embase database, CNKI database, Wanfang Database and Weipu database were searched by computer. The retrieval time was from June 2020 to search for a controlled study of the relationship between bipolar disorder (BD) or major depressive disorder and normal control peripheral IGF-1. Review Manager (version 5.3) software was used for meta-analysis.
RESULTS
A total of 14 articles in Chinese and English were included; 285 patients with BD and 503 patients with major depressive disorder. Meta-analysis showed that in comparison with the control group, IGF-1 levels in peripheral blood of patients with BD (MD =67.66, 95% CI: 7.01-128.31, P=0.03) and major depressive disorder (MD =8.01, 95% CI: 3.43-12.58, P=0.0006) were significantly increased. In the meta-analysis comparing the peripheral IGF-1 levels of patients before and after treatment, the results showed no significant change in the peripheral IGF-1 level before and after treatment (P=0.53).
CONCLUSIONS
High peripheral IGF-1 level is a related factor of BD and major depressive disorder, although this needs to be confirmed by further large sample studies.
Topics: Bipolar Disorder; Databases, Factual; Depressive Disorder, Major; Humans; Insulin; Insulin-Like Growth Factor I
PubMed: 33302664
DOI: 10.21037/apm-20-1967 -
Archives of Gerontology and Geriatrics 2021Biomarkers for delirium could increase diagnostic accuracy and may help to identify pathological pathways. Until now study findings concerning cytokine levels have been... (Meta-Analysis)
Meta-Analysis Review
Consistent patterns in the inconsistent associations of Insulin-like growth factor 1 (IGF-1), C-Reactive Protein (C-RP) and Interleukin 6 (IL-6) levels with delirium in surgical populations. A systematic review and meta-analysis.
BACKGROUND
Biomarkers for delirium could increase diagnostic accuracy and may help to identify pathological pathways. Until now study findings concerning cytokine levels have been inconsistent.
AIMS
Systematic review and meta-analysis investigating the association between peripheral levels of Insulin-like Growth Factor-1 (IGF-1), C-Reactive Protein (C-RP) and Interleukin-6 (IL-6) and delirium in surgical patients, and to explore if there are distinct/specific patterns that may potentially explain inconsistent results.
METHODS
PubMed, Scopus, CINAHL, Cochrane, and EMBASE databases were searched. Inclusion criteria were: prospective studies, surgical populations excluding preoperative delirium, available data. The following were collected: type of operation (orthopaedic, abdominal, etc), the timing of operation (acute, elective, both), demographics, number of participants with delirium, time of preoperative blood withdrawal, and preoperative levels of each biomarker.
RESULTS
Low levels of IGF-1 (n = 7 studies) are significantly associated with post-operative delirium in abdominal surgical samples. High levels of C-RP (n = 9) are associated with delirium in acute orthopaedic and elective abdominal operations. IL-6 (n = 14) is a significant predictor of post-operative delirium in a variety of surgical conditions (elective or acute).
DISCUSSION
A common pattern exists in the otherwise conflicting reported findings. This similarity may reflect different underling mechanisms and predisposing factors like cachexia and catabolic stages. It seems that delirium in abdominal surgery is triggered by IGF-1 disturbances, while in other surgeries by an inflammatory reaction.
CONCLUSIONS
Despite the contradictory results concerning the association of IGF-1, C-RP and IL-6 with postoperative delirium, the present meta-analysis shows that there are certain patterns. IL-6 seems a consistent predictor for delirium in surgical samples.
Topics: C-Reactive Protein; Delirium; Humans; Insulin-Like Growth Factor I; Interleukin-6; Prospective Studies
PubMed: 34536657
DOI: 10.1016/j.archger.2021.104518 -
Clinical Endocrinology Nov 2016Growth hormone (GH) and insulin-like growth factor I (IGF-I) are the principal biomarkers used to assess disease activity in acromegaly, and any discrepancy between them... (Meta-Analysis)
Meta-Analysis Review
The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis.
OBJECTIVE
Growth hormone (GH) and insulin-like growth factor I (IGF-I) are the principal biomarkers used to assess disease activity in acromegaly, and any discrepancy between them renders interpretation of results inconclusive. Purpose of this study was to assess the frequency of this discrepancy and identify parameters that might affect its occurrence.
DESIGN
A systematic review of MEDLINE and Scopus was performed (1987-2013) followed by a meta-analysis to address the frequency of discrepant results between GH and IGF-I levels. Meta-regression and subgroup analyses were performed assessing the effects of the year of publication, the different types of GH testing and GH assays used, as well as the impact of treatment with somatostatin analogues (SSAs) on the occurrence of this discrepancy.
RESULTS
The analysis retrieved 39 eligible studies totalling 7071 patients. The pooled discordance rate between GH and IGF-I was 25·7% (95% CI: 22·3-29·4), and the predominant format was that of elevated IGF-I with normal GH levels (15·3%, 95% CI: 12·5-18·7). No significant correlation between the discordance rate and the year of publication was shown; whereas, the use of ultrasensitive GH assays resulted in higher discordance rates (30·7%, 95% CI: 25·9-35·9 vs 19·8%, 95% CI: 14·1-27·2, P = 0·04) as did treatment with SSAs (32·5%, 95% CI: 27·8-37·4) vs (21·6%, 95% CI: 17·8-25·6, P = 0·001).
CONCLUSIONS
Discrepancy between GH and IGF-I results is encountered in a quarter of treated patients with acromegaly, especially when using ultrasensitive GH assays or in patients receiving SSAs, a fact that the clinician should take into consideration when making clinical decisions.
Topics: Acromegaly; Biomarkers; Growth Hormone; Humans; Insulin-Like Growth Factor I
PubMed: 27292418
DOI: 10.1111/cen.13129 -
In Vivo (Athens, Greece) 2020The insulin-like growth factor bioregulation system is implicated in cancer biology. Herein, we aim to review the evidence on the expression of the insulin-like growth... (Review)
Review
BACKGROUND/AIM
The insulin-like growth factor bioregulation system is implicated in cancer biology. Herein, we aim to review the evidence on the expression of the insulin-like growth factor 1 and 2 (IGF1 and IGF2), their receptors (IGF-Rs) and IGF-binding proteins (IGFBPs) in thyroid tissue and their possible association with benign and malignant thyroid nodular diseases.
MATERIALS AND METHODS
We systematically reviewed Pubmed and Scopus databases up to May 2020. A total of 375 articles were retrieved and analyzed.
RESULTS
Among 375 articles, 45 were included in this systematic review study. IGF1 was investigated in 31 studies, IGF2 in 1, IGF1 receptor in 15 and IGF-binding proteins in 13 articles. IGF1 expression in humans was dependent on the number and compound of benign nodules as well as the method of measurement. In differentiated thyroid carcinoma, a positive correlation between IGF1 and immunohistological stage was documented in some studies while in others only a positive trend was observed. IGF-1R and IGFBPs expression was higher in malignant rather than benign lesions. There was only a positive trend for increased IGF2 expression in malignancy, while IGFBPs were in most studies statistically increased in various cancer types compared to benign nodular disease.
CONCLUSION
The present data demonstrate that in most studies there is statistically positive expression of IGF-1 and less of IGF-2 in thyroid cancer compared to normal thyroid tissue.
Topics: Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Phosphorylation; Receptor, IGF Type 1; Signal Transduction; Thyroid Neoplasms
PubMed: 33144411
DOI: 10.21873/invivo.12141